Mutant ALK has been shown to signal through the Mitogen-activated protein kinase (MAPK) pathway [7], and although only a low level of RAS-MAPK pathway mutations were reported in neuroblastoma diagnosis samples [8], recent sequencing analyses have shown that RAS pathway mutations are increased in relapsing neuroblastoma [9], [10]. This evidence concerns the gene ALK and neuroblastoma.